# OGT‐Mediated O‐GlcNAcylation Stabilizes c‐Myc Activity and Promotes Chemoresistance in Triple‐Negative Breast Cancer

**Authors:** Jie Li, Jing Zhang

PMC · DOI: 10.1155/tbj/2120017 · The Breast Journal · 2026-02-27

## TL;DR

This study shows that OGT-mediated O-GlcNAcylation stabilizes c-Myc and promotes chemoresistance in triple-negative breast cancer.

## Contribution

The study identifies Thr-58 as a novel O-GlcNAcylation site on c-Myc that regulates its stability and chemoresistance in TNBC.

## Key findings

- Inhibition of OGT reduces c-Myc stability and chemoresistance in TNBC cells.
- O-GlcNAcylation at Thr-58 promotes c-Myc activity and colony formation.
- Mutation of Thr-58 decreases c-Myc expression and increases apoptosis in resistant cells.

## Abstract

The transcription factor c‐Myc is often overexpressed in chemotherapy‐resistant triple‐negative breast cancer (TNBC). c‐Myc function and stability are considered key factors regulating chemoresistance. Recent studies have revealed a potential link between the O‐linked β‐N‐acetylglucosamine modification (O‐GlcNAcylation) of c‐Myc and its function and stability; however, the underlying mechanisms remain unexplored. This study aimed to investigate the role of O‐GlcNAcylation in promoting chemoresistance and to explore the underlying mechanisms. A cisplatin (DDP)‐resistant MDA‐MB‐231 cell line was established using a dose escalation. CCK‐8, flow cytometry, and colony formation assays were used to evaluate cell resistance under different treatments. Western blotting and coimmunoprecipitation analyses were performed to evaluate the expression of c‐Myc and its O‐GlcNAcylation under different conditions. The possible O‐GlcNAcylation sites were predicted using DictyOGlyc 1.1. Inhibition of O‐linked N‐acetylglucosamine transferase (OGT) significantly suppressed colony formation and promoted apoptosis of DDP‐resistant cells. c‐Myc expression was downregulated when OGT‐mediated O‐GlcNAcylation was inhibited. Additionally, OGT interacted with c‐Myc, promoting its stability at the Thr58 residue. Mutation of Thr58 not only resulted in lower c‐Myc stability, reduced colony formation ability, and increased apoptosis but also resulted in a decrease in both the total expression and O‐GlcNAcylation of c‐Myc. Therefore, O‐GlcNAcylation at Thr‐58 regulates c‐Myc activity to promote chemoresistance of TNBC cells.

## Linked entities

- **Genes:** MYC (MYC proto-oncogene, bHLH transcription factor) [NCBI Gene 4609], OGT (O-linked N-acetylglucosamine (GlcNAc) transferase) [NCBI Gene 8473]
- **Proteins:** MYC (MYC proto-oncogene, bHLH transcription factor), OGT (O-linked N-acetylglucosamine (GlcNAc) transferase)
- **Chemicals:** cisplatin (PubChem CID 5460033)
- **Diseases:** triple-negative breast cancer (MONDO:0005494), breast cancer (MONDO:0004989)

## Full-text entities

- **Genes:** AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, Nfkb1 (nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105) [NCBI Gene 18033] {aka NF-KB1, NF-kappaB, NF-kappaB1, p105, p50, p50/p105}, Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}, MYC (MYC proto-oncogene, bHLH transcription factor) [NCBI Gene 4609] {aka MRTL, MYCC, bHLHe39, c-Myc}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, CTNNB1 (catenin beta 1) [NCBI Gene 1499] {aka CTNNB, EVR7, MRD19, NEDSDV, armadillo}, PGR (progesterone receptor) [NCBI Gene 5241] {aka NR3C3, PR}, ERBB2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 2064] {aka CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19}, POTEF (POTE ankyrin domain family member F) [NCBI Gene 728378] {aka A26C1B, POTE2alpha, POTEACTIN}, GSK3B (glycogen synthase kinase 3 beta) [NCBI Gene 2932], PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, ANXA5 (annexin A5) [NCBI Gene 308] {aka ANX5, CPB-I, ENX2, HEL-S-7, PP4, RPRGL3}, Stat3 (signal transducer and activator of transcription 3) [NCBI Gene 20848] {aka 1110034C02Rik, Aprf}, ESR1 (estrogen receptor 1) [NCBI Gene 2099] {aka ER, ESR, ESRA, ESTRR, Era, NR3A1}, Il6 (interleukin 6) [NCBI Gene 16193] {aka Il-6}, OGT (O-linked N-acetylglucosamine (GlcNAc) transferase) [NCBI Gene 8473] {aka HINCUT-1, HRNT1, MRX106, O-GLCNAC, OGT1, XLID106}, Ogt (O-linked N-acetylglucosamine (GlcNAc) transferase (UDP-N-acetylglucosamine:polypeptide-N-acetylglucosaminyl transferase)) [NCBI Gene 108155] {aka 1110038P24Rik, 4831420N21Rik, Ogtl}
- **Diseases:** metastasis (MESH:D009362), inflammation (MESH:D007249), cancer (MESH:D009369), toxicity (MESH:D064420), TNBC (MESH:D064726), breast cancer (MESH:D001943)
- **Chemicals:** crystal violet (MESH:D005840), propidium iodide (MESH:D011419), DDP (MESH:D002945), Cat #C1988 (-), penicillin (MESH:D010406), FITC (MESH:D016650), streptomycin (MESH:D013307), CO2 (MESH:D002245), CCK-8 (MESH:D012844), agarose (MESH:D012685), TB (MESH:D013725), TRIzol (MESH:C411644), CHX (MESH:D003513), SDS (MESH:D012967), PVDF (MESH:C024865), PBS (MESH:D007854), DMSO (MESH:D004121)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Mutations:** Ser234, Ser161, S161A, P0013F, T58A, Ser288
- **Cell lines:** MDA-MB-231 — Homo sapiens (Human), Breast adenocarcinoma, Cancer cell line (CVCL_0062), HEK293T — Homo sapiens (Human), Transformed cell line (CVCL_0063)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12947114/full.md

## Figures

21 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12947114/full.md

## References

44 references — full list in the complete paper: https://tomesphere.com/paper/PMC12947114/full.md

---
Source: https://tomesphere.com/paper/PMC12947114